Voyagers Capital
VC Fund
Voyagers Capital is a specialized investment company that concentrates on the medical and healthcare sector while considering both domestic and international markets.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Voyagers Capital invests in
Stages Voyagers Capital invests in
Countries Voyagers Capital invests in
Investment Focus
Industry
- Biotechnology 3 (60%)
- Medical 2 (40%)
- Health Care 2 (40%)
- Life Science 2 (40%)
- Pharmaceutical 2 (40%)
Stage
- Series A 2 (40%)
- Angel 1 (20%)
- Series C 1 (20%)
- Venture - Series Unknown 1 (20%)
Country
- China 4 (80%)
- United States 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
iCamumo
|
Aikai Biotech is focused on developing a new generation of off-the-shelf general-purpose cell therapy pharmaceuticals using iPSC. | $14.4M / Series A / Mar 09, 2026 | |
GeneMind Biosciences
|
GeneMind Biosciences is a domestic third-generation single-molecule gene sequencing system. GeneMind Biosciences has been fighting to provide better gene sequencing solutions for clinicians and researchers. A Gene sequencer is the crown jewel in the field of gene sequencing. Entrepreneurs will lead their innovations and breakthroughs throughunremitting research and exploration. GeneMind believes that the strong pass of the difficulty is like a wall of iron, yet with firm strides, we are conquering its summit. | $38.6M / Venture - Series Unknown / Mar 10, 2025 | |
|
Alpine Medical
|
Alpine focuses on the research and development and industrialization of innovative medical devices in the field of heart failure, and is committed to providing safe, effective and affordable treatment solutions for patients around the world. | $7M / Angel / Feb 22, 2025 | |
|
SanVectron
|
SanVectron is a medical device company specializing in the sales, production, and distribution of medical devices, as well as the sales of laboratory analysis instruments. | $27.4M / Series A / Dec 23, 2024 | |
Cullgen
|
Cullgen is a drug discovery service intended to create new drugs for the treatment of diseases that currently lack effective therapies. The company's services use protein degradation technology that focuses on the selective degradation of disease-causing proteins, a novel treatment for cancer, inflammatory and autoimmune diseases, includingtargets previously considered undruggable, enabling scientists with new means to develop novel therapeutic approaches for various diseases. | $35M / Series C / May 08, 2023 |
Co-Investors
Sansure Biotech
2 deals together
GNI Japan
1 deal together
InnoVision Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Voyagers Capital invest in?
Voyagers Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Angel stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Voyagers Capital last invest?
The most recent investment recorded for Voyagers Capital closed in Mar 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
